Clinical trial
Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)
NCT00396175 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00396175 |
|---|---|
| Title | Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) |
| Official title | A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Androgenetic Alopecia |
| Intervention type | Drug |
| Interventions | MK0906, finasteride / Duration of Treatment : 48 Weeks, Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks |
| Enrollment | 355 |
| Start date | Mar 1, 1998 |
| Primary completion | Jan 1, 2000 |
| First posted | Nov 6, 2006 |
| Last update posted | Feb 17, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: